Navidea Biopharmaceuticals Inc. (NAVB) Financials Nov 14, 2014, 4:28 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Navidea Biopharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 9.52M 10.7M 597,729 78,738 1.13M
Cost of Goods Sold (COGS) incl. D&A 3.13M 3.21M - - 736,996
COGS excluding D&A 2.8M 2.98M - - 332,815
Depreciation & Amortization Expense 333,749 223,460 176,544 200,222 404,181
Depreciation 202,703 215,462 175,296 198,822 400,304
Amortization of Intangibles 131,046 7,998 1,248 1,400 3,877
Gross Income 6.38M 7.49M - - 393,634
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 8.21M 13.8M 24.53M 27.87M 38.83M
Research & Development 4.97M 9.22M 15.15M 16.89M 23.71M
Other SG&A 3.24M 4.58M 9.37M 10.98M 15.12M
Other Operating Expense 0 0 0 0 0
Unusual Expense 34.37M 43.05M 952,375 (32,110) 1.48M
EBIT after Unusual Expense (34.37M) (43.05M) (952,375) 32,110 (1.48M)
Non Operating Income/Expense (3,422) 32,594 (3,211) (58,723) (16,863)
Non-Operating Interest Income 18,749 8,804 25,755 25,044 18,838
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 1.53M 554,988 13,330 1.17M 2.78M
Gross Interest Expense 1.53M 554,988 13,330 1.17M 2.78M
Interest Capitalized 0 0 0 0 0
Pretax Income (37.72M) (49.88M) (25.05M) (29.16M) (42.7M)
Income Tax 0 0 (7.88M) 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (37.72M) (49.88M) (17.17M) (29.16M) (42.7M)
Minority Interest Expense 0 0 0 0 0
Net Income (37.72M) (49.88M) (17.17M) (29.16M) (42.7M)
Extraordinaries & Discontinued Operations (1.89M) (86,597) 22.78M 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 19.45M 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (1.89M) (86,597) 3.33M 0 0
Net Income After Extraordinaries (39.61M) (49.96M) 5.61M (29.16M) (42.7M)
Preferred Dividends 240,000 8.21M 100,000 43,333 0
Net Income Available to Common (37.96M) (58.09M) (17.27M) (29.2M) (42.7M)
EPS (Basic) (0.54) (0.72) (0.15) (0.29) (0.35)
Basic Shares Outstanding 73.77M 80.73M 90.51M 99.06M 121.81M
EPS (Diluted) (0.54) (0.72) (0.15) (0.29) (0.35)
Diluted Shares Outstanding 73.77M 80.73M 90.51M 99.06M 121.81M
EBITDA (1.49M) (6.09M) (23.93M) (27.79M) (38.03M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Navidea Biopharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 9.52M 10.7M 597,729 78,738 1.13M
Cost of Goods Sold (COGS) incl. D&A 3.13M 3.21M - - 736,996
COGS excluding D&A 2.8M 2.98M - - 332,815
Depreciation & Amortization Expense 333,749 223,460 176,544 200,222 404,181
Depreciation 202,703 215,462 175,296 198,822 400,304
Amortization of Intangibles 131,046 7,998 1,248 1,400 3,877
Gross Income 6.38M 7.49M - - 393,634
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 8.21M 13.8M 24.53M 27.87M 38.83M
Research & Development 4.97M 9.22M 15.15M 16.89M 23.71M
Other SG&A 3.24M 4.58M 9.37M 10.98M 15.12M
Other Operating Expense 0 0 0 0 0
Unusual Expense 34.37M 43.05M 952,375 (32,110) 1.48M
EBIT after Unusual Expense (34.37M) (43.05M) (952,375) 32,110 (1.48M)
Non Operating Income/Expense (3,422) 32,594 (3,211) (58,723) (16,863)
Non-Operating Interest Income 18,749 8,804 25,755 25,044 18,838
Equity in Affiliates (Pretax) 0 0 0 - 0
Interest Expense 1.53M 554,988 13,330 1.17M 2.78M
Gross Interest Expense 1.53M 554,988 13,330 1.17M 2.78M
Interest Capitalized 0 0 0 0 0
Pretax Income (37.72M) (49.88M) (25.05M) (29.16M) (42.7M)
Income Tax 0 0 (7.88M) 0 0
Income Tax - Current Domestic 0 0 - - -
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 - - -
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (37.72M) (49.88M) (17.17M) (29.16M) (42.7M)
Minority Interest Expense 0 0 0 0 0
Net Income (37.72M) (49.88M) (17.17M) (29.16M) (42.7M)
Extraordinaries & Discontinued Operations (1.89M) (86,597) 22.78M 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 19.45M 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (1.89M) (86,597) 3.33M 0 0
Net Income After Extraordinaries (39.61M) (49.96M) 5.61M (29.16M) (42.7M)
Preferred Dividends 240,000 8.21M 100,000 43,333 0
Net Income Available to Common (37.96M) (58.09M) (17.27M) (29.2M) (42.7M)
EPS (Basic) (0.54) (0.72) (0.15) (0.29) (0.35)
Basic Shares Outstanding 73.77M 80.73M 90.51M 99.06M 121.81M
EPS (Diluted) (0.54) (0.72) (0.15) (0.29) (0.35)
Diluted Shares Outstanding 73.77M 80.73M 90.51M 99.06M 121.81M
EBITDA (1.49M) (6.09M) (23.93M) (27.79M) (38.03M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
